Copyright
©The Author(s) 2024.
World J Gastrointest Pathophysiol. Apr 22, 2024; 15(1): 91237
Published online Apr 22, 2024. doi: 10.4291/wjgp.v15.i1.91237
Published online Apr 22, 2024. doi: 10.4291/wjgp.v15.i1.91237
Parameters | n | PTB1 (%) | PTB2 (%) | PTB3 (%) | ITB1 (%) | ITB2 (%) | ITB3 (%) | DR1 (%) | DR2 (%) | DR3 (%) | TILs (%) | TILs (%) |
Age, yr | ||||||||||||
< 62.14 ± 12.00 | 64 | 11 (42.3) | 25 (59.5) | 28 (45.2) | 15 (48.4) | 14 (56.0) | 35 (47.3) | 29 (50.0) | 20 (52.6) | 15 (44.1) | 34 (50.0) | 30 (48.4) |
≥ 62.14 ± 12.00 | 66 | 15 (57.7) | 17 (40.5) | 34 (54.8) | 16 (51.6) | 11 (44.0) | 39 (52.7) | 29 (50.0) | 18 (47.4) | 19 (55.9) | 34 (50.0) | 32 (51.6) |
Gender | ||||||||||||
Male | 77 | 16 (61.5) | 26 (61.9) | 35 (56.5) | 18 (58.1) | 19 (76.0) | 40 (54.1) | 43 (74.1) | 23 (60.5) | 11 (32.4)a | 36 (52.9) | 41 (66.1) |
Female | 53 | 10 (38.5) | 16 (38.1) | 27 (43.5) | 13 (41.9) | 6 (24.0) | 34 (45.9) | 15 (25.9) | 15 (39.5) | 23 (67.6) | 32 (47.1) | 21 (33.9) |
Diameter | ||||||||||||
< 1.86 ± 1.02 | 84 | 16 (61.5) | 29 (69.0) | 39 (62.9) | 16 (51.6) | 19 (76.0) | 49 (66.2) | 34 (58.6) | 28 (73.7) | 22 (64.7) | 47 (69.1) | 37 (59.7) |
≥ 1.86 ± 1.02 | 46 | 10 (38.5) | 13 (31.0) | 23 (37.1) | 15 (48.4) | 6 (24.0) | 25 (33.8) | 24 (41.4) | 10 (26.3) | 12 (35.3) | 21 (30.9) | 25 (40.3) |
Invasion | ||||||||||||
T1 | 7 | 5 (19.2) | 2 (4.8) | 0b | 4 (12.9) | 1 (4.0) | 2 (2.7) | 3 (5.2) | 3 (7.9) | 1 (2.9) | 4 (5.9) | 3 (4.8) |
T2 | 39 | 4 (15.4) | 15 (35.7) | 20 (32.3) | 12 (38.7) | 8 (32.0) | 19 (25.7) | 22 (37.9) | 9 (23.7) | 8 (23.5) | 18 (26.5) | 21 (33.9) |
T3 | 52 | 11 (42.3) | 15 (35.7) | 26 (41.9) | 10 (32.3) | 6 (24.0) | 36 (48.6) | 25 (43.1) | 16 (42.1) | 11 (32.4) | 27 (39.7) | 25 (40.3) |
T4 | 32 | 6 (23.1) | 10 (23.8) | 16 (25.8) | 5 (16.1) | 10 (40.0) | 17 (23.0) | 8 (13.8) | 10 (26.3) | 14 (41.2) | 19 (27.9) | 13 (21.0) |
LNM | ||||||||||||
Absent | 82 | 23 (88.5) | 29 (69.0) | 30 (48.4)a | 29 (93.5) | 16 (64.0) | 37 (50.0)a | 43 (74.1) | 23 (60.5) | 16 (47.1)c | 38 (55.9) | 44 (71.0) |
Present | 48 | 3 (11.5) | 13 (31.0) | 32 (51.6) | 2 (6.5) | 9 (36.0) | 37 (50.0) | 15 (25.9) | 15 (39.5) | 18 (52.9) | 30 (44.1) | 18 (29.0) |
Metastasis | ||||||||||||
Absent | 106 | 26 (100.0) | 31 (73.8) | 49 (79.0)c | 21 (67.7) | 23 (92.0) | 62 (83.8) | 49 (84.5) | 33 (86.8) | 24 (70.6) | 55 (80.9) | 51 (82.3) |
Present | 24 | - | 11 (26.2) | 13 (21.0) | 10 (32.3) | 2 (8.0) | 12 (16.2) | 9 (15.5) | 5 (13.2) | 10 (29.4) | 13 (19.1) | 11 (17.7) |
Stage | ||||||||||||
I | 21 | 11 (42.3) | 9 (21.4) | 1 (1.6)a | 10 (32.3) | 6 (24.0) | 5 (6.8)a | 13 (22.4) | 6 (15.8) | 2 (5.9) | 13 (19.1) | 8 (12.9) |
II | 38 | 6 (23.1) | 12 (28.6) | 20 (32.3) | 8 (25.8) | 4 (16.0) | 26 (35.1) | 20 (34.5) | 11 (28.9) | 7 (20.6) | 18 (26.5) | 20 (32.3) |
III | 48 | 8 (30.8) | 11 (26.2) | 29 (46.8) | 3 (9.7) | 14 (56.0) | 31 (41.9) | 16 (27.6) | 15 (39.5) | 17 (50.0) | 24 (35.3) | 24 (38.7) |
IV | 23 | 1 (3.8) | 10 (23.8) | 12 (19.4) | 10 (32.3) | 1 (4.0) | 12 (16.2) | 9 (15.5) | 6 (15.8) | 8 (23.5) | 13 (19.1) | 10 (16.1) |
Subtype | ||||||||||||
Intestinal | 100 | 24 (92.4) | 39 (92.9) | 37 (59.7)a | 30 (96.8) | 21 (84.0) | 49 (66.2)b | 47 (81.0) | 28 (73.7) | 25 (73.5) | 52 (76.5) | 48 (77.4) |
Diffuse | 19 | 1 (3.8) | 3 (7.1) | 15 (24.2) | 1 (3.2) | 2 (8.0) | 16 (21.6) | 8 (13.8) | 4 (10.5) | 7 (20.6) | 10 (17.7) | 9 (14.5) |
Mixed | 11 | 1 (3.8) | 0 | 10 (16.1) | 0 | 2 (8.0) | 9 (12.2) | 3 (5.2) | 6 (15.8) | 2 (5.9) | 6 (8.8) | 5 (8.1) |
LVI | ||||||||||||
Absent | 89 | 14 (53.8) | 28 (66.7) | 47 (75.8) | 16 (51.6) | 19 (76.0) | 54 (73.0) | 39 (67.2) | 24 (63.2) | 26 (76.5) | 45 (66.2) | 44 (71.0) |
Present | 41 | 12 (46.2) | 14 (33.3) | 15 (24.2) | 15 (48.4) | 6 (24.0) | 20 (27.0) | 19 (32.8) | 14 (36.8) | 8 (23.5) | 23 (33.8) | 18 (29.0) |
PNI | ||||||||||||
Absent | 94 | 16 (61.5) | 28 (66.7) | 50 (80.6) | 18 (58.1) | 19 (76.0) | 57 (77.0) | 43 (74.1) | 25 (65.8) | 26 (76.5) | 52 (76.5) | 42 (67.7) |
Present | 36 | 10 (38.5) | 14 (33.3) | 12 (19.4) | 13 (49.0) | 6 (24.0) | 11 (23.0) | 15 (25.9) | 13 (34.2) | 8 (23.5) | 16 (23.5) | 20 (32.3) |
Survival | ||||||||||||
Deceased | 100 | 9 (34.6) | 29 (69.0) | 62 (100.0)a | 8 (25.8) | 20 (80.0) | 72 (97.3)a | 40 (69.0) | 29 (76.3) | 31 (91.2) | 56 (82.4) | 44 (71.0) |
Alive | 30 | 17 (65.4) | 13 (31.0) | 0 | 23 (74.2) | 5 (20.0) | 2 (2.7) | 18 (31.0) | 9 (23.7) | 3 (8.8) | 12 (17.6) | 18 (29.0) |
PTB | ||||||||||||
PTB1 | 26 | - | - | - | 17 (54.8) | 3 (12.0) | 6 (8.1)a | 15 (25.9) | 8 (21.1) | 3 (8.8)d | 10 (14.7) | 16 (25.8)b |
PTB2 | 42 | - | - | - | 14 (45.2) | 18 (72.0) | 10 (13.5) | 24 (41.4) | 12 (31.6) | 6 (17.7) | 17 (25.0) | 25 (40.3) |
PTB3 | 62 | - | - | - | 0 | 4 (16.0) | 58 (78.4) | 19 (32.8) | 18 (47.4) | 25 (73.5) | 41 (60.3) | 21 (33.9) |
ITB | ||||||||||||
ITB1 | 31 | - | - | - | - | - | - | 21 (36.2) | 8 (21.1) | 2 (5.9)d | 9 (13.2) | 22 (35.5)d |
ITB2 | 25 | - | - | - | - | - | - | 13 (22.4) | 6 (15.8) | 6 (17.6) | 13 (19.2) | 12 (19.4) |
ITB3 | 74 | - | - | - | - | - | - | 24 (41.4) | 24 (63.2) | 26 (76.5) | 46 (67.6) | 28 (45.1) |
DR | ||||||||||||
DR1 | 58 | - | - | - | - | - | - | - | - | - | 22 (32.4) | 36 (58.0)b |
DR2 | 38 | - | - | - | - | - | - | - | - | - | 24 (35.2) | 14 (22.6) |
DR3 | 34 | - | - | - | - | - | - | - | - | - | 22 (32.4) | 12 (19.4) |
- Citation: Yavuz A, Simsek K, Alpsoy A, Altunay B, Gedik EO, Unal B, Bassorgun CI, Tatli AM, Elpek GO. Prognostic significance of tumor budding, desmoplastic reaction, and lymphocytic infiltration in patients with gastric adenocarcinoma. World J Gastrointest Pathophysiol 2024; 15(1): 91237
- URL: https://www.wjgnet.com/2150-5330/full/v15/i1/91237.htm
- DOI: https://dx.doi.org/10.4291/wjgp.v15.i1.91237